The myeloperoxidase (MPO)-positivity of blasts in bone marrow smears is an important marker for not only the diagnosis, but also the prognosis of acute myeloid leukemia (AML). To investigate the relationship between genetic alterations and MPO-positivity, we performed targeted sequencing for 51 genes and 10 chimeric gene transcripts in 164 newly diagnosed de novo AML patients; 107 and 57 patients were classified as AML with > 50% MPO-positive blasts (MPO-high group) and ≤50% MPO-positive blasts, (MPO-low group), respectively. The univariate analysis revealed that RUNX1-RUNX1T1 (P < 0.001), the KIT mutation (P < 0.001), and CEBPA double mutation (P = 0.001) were more likely to be found in the MPO-high group, while the DNMT3A mutation (P = 0.001), FLT3 tyrosine kinase domain mutation (P = 0.004), and TP53 mutation (P = 0.020) were more likely to be present in the MPO-low group. Mutations in genes related to DNA hypermethylation signatures (IDH1, IDH2, TET2, and WT1 genes) were more frequent in the MPO-high group (P = 0.001) when patients with fusion genes of core-binding factors were excluded from the analysis. Our results suggest that MPO-positivity of blasts was related with the distinct gene mutation patterns among de novo AML patients.
Introduction
The expression of myeloperoxidase (MPO), a microbicidal protein, is a definitive marker for the diagnosis of acute myeloid leukemia (AML) in the French-American-British (FAB) and World Health Organization (WHO) classifications [1] [2] [3] . Although its expression in blasts (≥3%) represents a commitment to a myeloid lineage, the percentage of MPO-positive blasts varies widely among patients with AML. In the AML-92 and -201 clinical trials for AML patients conducted by the Japan Adult Leukemia Study Group (JALSG), patients with a high percentage of MPO-positive blasts had a significantly better outcome than those with a low percentage [4, 5] . Thus, the MPO-positivity of AML blasts is not only a lineage marker, but also a significant prognostic factor for AML patients. The MPO-positivity of blasts was also shown to have a significant impact on prognosis, even restricted to patients with a normal karyotype [4] . In vitro experiments also suggested that the expression of MPO in immature leukemia cells enhanced the sensitivity against cytarabine arabinoside [6] . Another clinical study, in which high levels of MPO mRNA in CD133-positive AML cells was significantly related with a better overall survival, further indicated that the MPO gene expression in immature leukemia cells could reflect the genetic and/or epigenetic profiles relating to the sensitivity against chemotherapy [7] .
AML is highly heterogeneous for genetic and epigenetic alterations. Mutations in the NPM1 and CEBPA genes are now markers of new disease entities for de novo AML in the WHO 2016 classification [3] . As indicated by recent studies, alterations in several genes are prognostic factors for patients treated with intensive chemotherapy (e.g. FLT3, DNMT3A, TP53, MLL, NPM1, and CEBPA genes) [8] [9] [10] . Genes coding epigenetic modifiers, spliceosome components, and cohesion complexes are also mutated in AML, and have been reported to affect its prognosis [11] [12] [13] . European LeukemiaNet (ELN) has recommended a risk stratification system based on the cytogenetic status and genetic alterations, such as FLT3, NPM1, and CEBPA genes [10] . In JALSG AML201 study, we have proposed that the overall survival of AML patients could be more clearly stratified by including the mutational status of DNMT3A, MLL-PTD, and TP53 genes than the ELN system [12] . Accordingly, a comprehensive gene sequencing strategy is required to improve the quality of diagnoses, risk stratification, and treatment selection for AML.
We previously revealed that the CEBPA double mutation (CEBPA DMt) was identified only among AML patients with a high percentage of MPO-positive blasts [14] , and we also demonstrated that the MPOpositivity of AML blasts correlated with distinct DNA methylation profiling [15] . These findings suggest the presence of a specific relationship between MPO-positivity and gene mutations in AML. Due to the crucial roles of MPO-positivity and genetic alterations in the diagnosis and management of AML, it will be of interest to further investigate the relationship between gene mutation profiling and MPOpositivity. To address this issue, we performed a comprehensive analysis of genetic alterations in 51 genes and 10 fusion genes among 164 patients registered in the JALSG AML 201 study.
Patients and methods

Patients and samples
The present study included 164 adults with newly diagnosed de novo AML who were registered in the JALSG AML201 study (UMIN Clinical Trial Cord Registry C000000157). Patients with acute promyelocytic leukemia, a prior history of myelodysplastic syndromes, unexplained hematological abnormalities before the diagnosis of AML, a history of chemotherapy and/or radiation therapy, and exposure to toxic reagents were excluded.
A cytogenetic G-banding analysis was performed using standard methods and classified according to the Medical Research Council classification [16] . We also examined the presence of 10 chimeric gene transcripts (Major BCR-ABL1, Minor BCR-ABL1, RUNX1-RUNX1T1, CBFB-MYH11, DEK-NUP214, NUP98-HOXA9, MLL-MLLT1, MLL-MLLT2, MLL-MLLT3, and MLL-MLLT4) by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) as previously reported [17] .
We obtained informed consent from all patients in this study to use their samples (bone marrow cells) for a gene mutation analysis and banking. This study was approved by the Ethical Committee of each participating institute, and conducted in accordance with the Declaration of Helsinki.
Morphological central review
The Central Committee for Morphology of the JALSG reviewed slides of bone marrow and peripheral blood at diagnosis, and the morphological diagnosis of AML was reached based on the FrenchAmerican-British (FAB) classification. The percentage of MPO-positive blasts was assessed by counting 100 blasts on bone marrow smears stained for MPO with the diaminobenzidine (DAB) method.
DNA sequencing of and a mutation analysis on 51 genes
High-molecular-weight DNA and total RNA were extracted from bone marrow samples using standard methods. A custom-made oligonucleotide probe library was designed to capture the exons of 51 genes that have been recurrently identified in myeloid neoplasms. A detailed methodology and the panel of genes used in this study were previously reported [12] . In brief, captured and enriched exons were subjected to targeted sequencing on Illumina HiSeq (Illumina, San Diego, CA, USA) [12] . Sequence variation annotation was performed using the dbSNP database (Database of Single Nucleotide Polymorphisms) (https:// www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?build_id= 131), followed by mutation characterization. Each predicted variant sequence was confirmed by Sanger sequencing. A mutational analysis for the internal tandem duplication of the FLT3 gene (FLT3-ITD) and partial tandem duplication of the MLL gene (MLL-PTD) was performed as previously reported [18] .
2.4.
Grouping by MPO-positivity, gene categories, and gene alterations AML patients were divided into two groups by the positivity of MPO enzymatic activity: AML patients with > 50% MPO-positive blasts (MPO-high group) and those with ≤50% MPO-positive blasts (MPOlow group) [4] [5] [6] 14, 15] . Patients who had chromosomal abnormalities and/or the fusion genes of t(8;21)(q22;q22); RUNX1-RUNX1T1 or inv (16)(p13q22); CBFB-MYH11 were classified as core binding factor AML (CBF-AML).
Genetic alterations have been functionally classified into activated signaling gene mutations (mutations in the FLT3, KIT, K-RAS, N-RAS, PTPN11, JAK1, and JAK3 genes), which induce the constitutive activation of intracellular signals that contribute to growth and survival, and myeloid transcription factor gene mutations (mutations in the CEBPA, GATA2, RUNX1, and ETV6 genes) that block differentiation and/or enhance self-renewal by altered factors. Genes that code proteins to control cell growth (TP53, PHF6, and CBL genes) were defined as tumor suppressor genes. Genes that code proteins related to DNA methylation (DNMT3A, IDH1, IDH2, TET2, and WT1 genes) were defined as DNA methylation-related genes [19] [20] [21] [22] . Genes that code proteins related to chromatin modifications (KDM6A, MLL, MLL-PTD, DOT1L, ASXL1, ATRX, EZH2, and PBRM1 genes) were defined as chromatin modifiers [12, 23] . Other gene alterations were classified as NOTCH family genes (NOTCH1 and NOTCH2), cohesion complex genes (SMC1A, SMC3, STAG2, and RAD21), BCOR family genes (BCOR and BCORL1), NCOR family genes (NCOR1, NCOR2, and DIS3), and spliceosome genes (SF3B1, U2AF1, SRSF2, and ZRSR2) [12] .
In the JALSG AML 201 study [5] , complete remission (CR) was defined as normal marrow cellularity with < 5% blast cells with nearnormal peripheral blood cell counts [24] .
Statistical analysis
Differences in continuous variables were analyzed by the Wilcoxon rank-sum test for their distributions between two groups. The frequencies of gene mutations and the CR rate were analyzed by EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [25] . In all analyses, P-values were two-tailed, and a P-value of less than 0.05 was considered to indicate a significant difference.
Results
Patient characteristics by the percentage of MPO-positive blasts
Among 164 patients, 107 were classified into the MPO-high group and 57 into the MPO-low group (Table 1) . A significant difference was observed in the distribution of AML subtypes according to the FAB classification between two groups (P < 0.001). AML cases in the MPO-high group were mainly classified as FAB-M2 (61.7%), while FAB-M4 was dominant in the MPO-low group (43.6%). The cytogenetic risk was significantly different between the MPO-high and −low groups (P < 0.001). Fifty patients were diagnosed with CBF-AML; 48 had favorable karyotypes, such as t(8;21) or inv(16)/t(16;16), while 2 with normal karyotypes were classified as CBF-AML by the presence of a specific fusion gene (CBFB-MYH11). Among 104 cases with cytogenetic intermediate risk, both MPO-high and -low patients were found (59 in MPO-high and 45 in MPO-low groups). Complex karyotypes with or without monosomy 7 or the partial deletion of the long arm of chromosome 7 were detected only in the MPO-low group. CR rates were significantly different between the two groups based on the MPO-positivity of blasts (Table 1 , P = 0.013). In the analysis of patients with non-CBF-AML, a slight difference was observed in the CR rate between the two groups (P = 0.083): the CR rates of the MPO-high and -low groups were 83.1% and 67.3%, respectively.
Frequencies of gene alterations
Using target sequencing, mutations were detected in 44 out of the 51 genes tested, and RT-qPCR identified 6 fusion transcripts among 164 patients ( Fig. 1 and Supplemental Table 1 ). No gene mutation or fusion transcript was detected in 3 patients in this study, 2 of whom had normal karyotypes. Each position and type of mutation have been reported previously [12] . We were unable to completely confirm whether all identified mutations were somatic because no germline material was available in this study. Accordingly, it was possible that a part of mutations could be rare SNPs. The frequencies of gene mutations were shown in Supplemental Table 1 , which was reported previously [12] . The mutations in the CEBPA gene were divided into CEBPA D-Mt (n = 16, 9.8%) and the CEBPA single mutation (CEBPA S-Mt) (n = 10, 6.1%). The mutations in DNA methylation-related genes other than DNMT3A were identified in 28 patients (17.1%), including mutations in the IDH1 in 9 (5.5%), IDH2 in 8 (4.9%), TET2 in 12 (7.3%), and WT1 in 12 (7.3%).
Comparison of gene alterations by the MPO-positivity of blasts
No significant difference was observed in the number of mutated genes per patient between the MPO-high and MPO-low groups (P = 0.252) (Supplemental Fig. 1 ). The mean number of mutated genes was 2.61 ± 0.12 and 2.37 ± 0.19 in the MPO-high and −low groups, respectively. However, the profile of mutated genes and fusion transcripts differed by the MPO-positivity of blasts (Fig. 2) . A correlation was observed between CBF-fusion genes (i.e. RUNX1-RUNX1T1 or CBFB-MYH11 transcripts) and high MPO-positivity (P < 0.001), which was consistent with the relationship between favorable karyotypes and the MPO-high group. A mutation in the KIT gene also correlated with high MPO-positivity (P < 0.001). The presence of KIT mutations were mostly restricted to patients with CBF-AML, as previously shown (23 out of 26 cases). Mutations in the CEBPA gene were also significantly more frequent in the MPO-high group (25 out of 26 cases, P < 0.001). When single and double mutations were separately tested, CEBPA D-Mt, but not CEBPA S-Mt, correlated with high MPO-positivity (P = 0.001). The presence of CBF-fusion genes and the CEBPA mutation was mutually exclusive among MPO-high patients. There were several gene mutations that correlated with low MPO-positivity; mutations in the DNMT3A (P = 0.001) and TP53 (P = 0.020) genes, and FLT3-TKD (P = 0.004). Among AML patients in the MPO-low group, the DNMT3A mutation was mutually exclusive with the TP53 mutation (see Fig. 1 ).
Distinct gene mutations in patients with non-CBF-AML
As demonstrated above, in MPO-high group, CBF-fusion genes were the most frequent alteration. In terms of the overlap pattern with mutated genes based on the functional classification, mutations in activated signaling genes were frequently detected among cases with CBFfusion genes (Fig. 3) , which was in good accordance with the "2-hit" genetic model of class I and class II [8, 18, 26] . On the contrary, among cases with non-CBF-AML, such genetic model was less consistent among non-CBF-AML cases, and the co-occurrence with DNA methylation-related gene mutation and other gene mutation tended to be more frequently observed. These results indicated the bias of genetic profiles of CBF-AML. To find the characteristic genetic alteration other than CBF-fusion genes, we next compared mutated genes and fusion transcripts with the positivity of MPO, excluding CBF-AML patients. Among patients with non-CBF-AML, the number of mutated genes showed no significant difference regardless of the MPO-positivity of blasts (P = 0.0490): 2.59 ± 0.17 and 2.42 ± 0.19 in the MPO-high and −low groups, respectively (Supplemental Fig. 2 ). The frequencies of mutated genes among these patients were as follows: mutations in the FLT3 (n = 36, 31.6%), NPM1 (n = 28, 24.6%), CEBPA (n = 26, 22.8%), and DNMT3A (n = 24, 21.1%) genes, which were identified in more than 10% of patients with non-CBF-AML. We then compared the frequency of gene alterations by the MPO-positivity of blasts (Fig. 4) . CEBPA D-Mt and CEBPA S-Mt both correlated with high MPO-positivity (P < 0.001 and P = .017, respectively), and the specificities of CEBPA D-Mt and CEBPA S-Mt were 100.0% and 98.1%, respectively, in these patients. A mutation in the IDH2 gene was associated with high MPOpositivity (P = 0.062). In contrast, the frequency of FLT3-TKD was significantly higher in AML patients in the MPO-low group (P = 0.026), the specificity of which was 96.6%. An association was observed between the DNMT3A mutation and low MPO-positivity (P = 0.065), even among patients with non-CBF-AML. The specificity of the DNMT3A mutation was 86.4% in these patients. We were interested in gene mutations related to DNA methylation because of our previous study on the relationship between the MPOpositivity of blasts and DNA methylation profiles [15] . IDH1/2-or TET2-mutated hematopoietic cells display an overlapping DNA hypermethylation signature that correlates with a decrease in 5-hydroxymethylcytosine [19] . Moreover, the loss-of-function mutations in WT1 gene has been reported to have the same consequence as loss-offunction mutations in TET2 gene in terms of epigenetic regulation. Based on the previous and present studies showing the mutually exclusive mutations between IDH1, IDH2, TET2, and WT1 in AML [29, 30] , we evaluated the relationship between the MPO-positivity of blasts and mutations in the IDH1/2, TET2, and WT1 (IDH1/2&TET2&WT1) genes. Although no single mutation showed a significant relationship, mutations in the IDH1/2&TET2&WT1 group correlated with high MPO-positivity (P = 0.001), the specificity of which was 83.6%. In the MPOhigh group, 40 out of 59 patients had either the CEBPA or IDH1/2& TET2&WT1 mutation; one patient had the CEBPA D-Mt and TET2 mutations. CEBPA D-Mt and/or IDH1/2&TET2&WT1 were mutated with 67.8% sensitivity and 83.6% specificity in these patients. The analysis 
Discussion
We herein focused on the relationship between the MPO-positivity of blasts by peroxidase staining and gene alterations using targeted sequencing. To the best of our knowledge, this is the first study to evaluate MPO-positivity as an indicator of the distinct pattern of gene alterations. The RUNX1-RUNX1T1 fusion gene, CEBPA D-Mt, and IDH1/ 2&TET2&WT1 mutations were more likely to be identified in the MPOhigh group, whereas mutations in the DNMT3A and TP53 genes were more likely to be identified in the MPO-low group. These results indicate that the MPO-positivity of blasts correlates with characteristic pattern of some gene alterations in patients with de novo AML.
The RUNX1-RUNX1T1 fusion gene was the most frequently observed in the MPO-high group, which showed high specificity [2, 27] . AML with the CBFB-MYH11 fusion gene is generally known to display high MPO-positivity [2] , although our results did not show this due to the small number of patients with the CBFB-MYH11 fusion gene. In addition, CBF-fusion genes were likely to co-occur with activated signaling gene mutations, such as KIT gene mutation, as reported previously [28] [29] [30] , but this trend was less likely in non-CBF-AML patients. Provided that carefully designed prospective study confirmed the prognostic impact of activated signaling gene mutations in CBF-AML patients, our findings would further emphasize a high diagnostic value in the detection of the co-occurrence of both CBF-fusion genes and the mutations in activated signaling genes in MPO-high group.
CEBPA D-Mt was identified in the MPO-high group with high specificity, which was mutually exclusive with CBF-AML. Our previous analysis also indicated that CEBPA D-Mt was associated with high MPOpositivity in AML patients having normal karyotypes [14] . Therefore, the present study using a comprehensive analysis further confirmed the relationship between CEBPA D-Mt and MPO-positivity. Moreover, because the WHO 2016 classification suggested the new entity "AML with CEBPA D-Mt" showing a favorable prognosis [3] , screening for mutations in the CEBPA gene was considered for patients with high MPOpositivity, but not classified as CBF-AML.
The most interesting result of the present study was that MPO-positivity correlated with the mutations in DNA methylation-related genes. The DNMT3A mutation was significantly more prevalent in the MPO-low group. In contrast, the prevalence of IDH1/2&TET2&WT1 mutations was higher in the MPO-high group when patients with CBF-AML were excluded. DNMT3A and IDH1/2&TET2&WT1 seem biochemically opposite from the point of functions as DNA methylation machinery, and MPO-positivity of blast was reported to correlate with the distinct DNA methylation profile [15] . Based on these results, we speculate that the MPO-positivity would reflect the distinct DNA methylation status of leukemia cells, which could be induced by the variety of mutational situations in DNA methylation-related genes. The presence of DNA methylation-related gene mutations may affect the selection of therapeutic strategies for patients with de novo AML in future. Several potent IDH1 and IDH2 mutant-targeting inhibitors (e.g. AG-221, AG-120, and IDH305) are currently being tested in clinical trials [31] [32] [33] . Furthermore, the DNMT3A mutation was reported to confer anthracycline resistance on AML cells [34] . Because it is possible that DNA methylation-related gene mutation will have an increasing impact on the selection of therapeutic option for AML in coming years, the attempt to the integrate the data about these gene mutational status into the traditional diagnostic modality, including the evaluation of MPO-positivity, should be required.
It is important to note that the MPO-low group was more likely to have the TP53 mutation, which was associated with a poor prognosis in de novo AML treated with chemotherapy and transplantation. Previous studies revealed that the TP53 mutation co-occurred in approximately 70% of de novo AML patients with adverse-risk karyotypes, such as the complex karyotype [13, 35, 36] , but it can be detected in AML without adverse karyotype. Considering these situations, the mutational status in TP53 genes should be carefully evaluated in the MPO-low group regardless of karyotype.
There were several limitations in the present study. We were unable to evaluate the impact of some mutated genes that were identified at lower frequencies in the present study. An analysis of how the position and type of each gene mutation affected MPO-positivity was insufficient due to the small number of each mutation. Large-scale studies are warranted in the future to clarify the relationship between MPO-positivity and gene alterations in more detail.
In summary, MPO-positivity of blasts was significantly related to the underlying genetic alterations, such as CBF-fusion genes, DNA methylation-related genes, and mutations in CEBPA and TP53, among the patients with de novo AML. It remains elucidated regarding how these alterations affect the expression level of MPO in leukemia blasts and prognosis of AML. 
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